1. ALLA AKTIER
  2. NYHETER
  3. LUMITO

Lumito

Nyheter Lumito Nyheter alla bolag
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!

Lumito has started an internal pilot study for multiplexing

Lumito has started a pilot study where the aim is to investigate the possibilities of multiplexing by adding another nanoparticle label to the company's unique UCNP-based technology.

There is a pronounced need from the market regarding requests for multiplexing to facilitate further and streamline the work within tissue analysis. Lumito already offers multiplexing with today's product by combining chromogenic labelling with the company's own UCNP labelling in the same image.
 

- The development of our first reagent product, SCIZYS Erbium Kit, is now complete, and our internal development resources can now focus on the next-generation product. It feels very encouraging and strategic right now to start this project, comments Lumito's CEO, Mattias Lundin.

 
Multiplexing is a technique that allows for the simultaneous analysis of multiple biomarkers within a single tissue sample. The company assesses that competitiveness increases further by offering yet another UCNP marking in the same image.

For further information, please contact:

Mattias Lundin, CEO Lumito
E-mail: ml@lumito.se
Ph: +46 76 868 45 09 

Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Lumito has started an internal pilot study for multiplexing

Datum 2023-11-01, kl 10:05
Källa MFN
Bifogade filer
Lumito has started an internal pilot study for multiplexing